PubMed Health⌕ Search

Biomedical subjects

W Schiess

Publications and source records attributed to W Schiess.

9 recordsLinked to original sources
PubMed1992

Hyaluronidase enhances the activity of adriamycin in breast cancer models in vitro and in vivo.

The effect of hyaluronidase and a combination of hyaluronidase with Adriamycin was investigated on several breast cancer models in vitro and in vivo. In vitro enzyme treatment (using concentrations up to 80,000 IU/1) of murine (MXT-, MXT +/-, and MXT+) and human (MCF-7, ZR-75-1 and T-47-D) breast cancer cell lines did not inhibit tumour cell proliferation (measured by a kinetic crystal violet assay) in either case. Although high-dose hyaluronidase (1.2 x 10(6) IU/kg) was ineffective, when administered peritumourally to the MXT M3.2 mammary carcinoma of the B6D2F1 mouse, it is remarkable that five "megadoses" were excellently tolerated. However, the antineoplastic activity of Adriamycin against the oestrogen-receptor-positive variant of the MXT tumour was significantly enhanced by combination with concentrations of hyaluronidase that were inactive per se, both in vitro and in vivo. Interestingly, the enhancement of the in vivo antitumour activity was not compromised by toxic side-effects.

Animals↗
PubMed1986

Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.

Twelve subjects with chronic obstructive lung disease and a partially reversible obstruction received increasing single doses of bopindolol (1, 2, 4, and 8 mg), pindolol (7.5, 15, and 30 mg), and atenolol (50 and 100 mg). Resting heart rate and blood pressure were reduced in a dose-dependent fashion. The actions of the drugs on lung function were assessed by whole body plethysmography. Pindolol did not influence mean airway resistance (Raw). Bopindolol (1, 2 and 4 mg) and atenolol (50 mg) exhibited a neutral effect on mean Raw. Atenolol (100 mg) and to a lesser extent bopindolol (8 mg) induced a long-lasting increase in mean Raw.

Adrenergic beta-Antagonists↗
PubMed1986

Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease.

Twelve subjects with chronic obstructive lung disease and a partially reversible obstruction received increasing single doses (1, 2, 4, and 8 mg) of bopindolol, (a new beta 1- and beta 2-adrenoceptor blocking drug with intrinsic sympathomimetic activity), pindolol (7.5, 15, and 30 mg), and atenolol (50 and 100 mg). The actions of the drugs on lung function were assessed by whole-body plethysmography. Pindolol did not influence mean airway resistance (Raw). Bopindolol 1, 2, and 4 mg and atenolol 50 mg also exhibited a neutral effect on mean Raw. Atenolol 100 mg, however, induced a long-lasting increase in mean Raw, which was to a lesser extent the case with bopindolol 8 mg. Six of the 12 subjects tested reacted more sensibly. Increases in Raw of more than 10% were observed with bopindolol 2 mg (1 subject), bopindolol 4 mg (4 subjects), pindolol 30 mg (3 subjects), and atenolol 50 mg (3 subjects). This clearly points toward a potential risk of eventually developing severe bronchospasm with each type of beta-adrenoceptor blocking drug in patients with chronic obstructive lung disease and a reversible component of the bronchial obstruction. Nevertheless it is concluded that beta-adrenoceptor blocking drugs with intrinsic sympathomimetic activity such as bopindolol and pindolol compare favorably with cardioselective agents such as atenolol.

Adrenergic beta-Antagonists↗
PubMed1986

Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.

Abrupt withdrawal of beta-adrenoceptor antagonists may lead to "rebound effects." To investigate the position of the new nonselective beta-adrenoceptor antagonist bopindolol [with moderate intrinsic sympathomimetic activity (ISA)], this drug was compared with propranolol (no ISA), alprenolol (weak ISA), and pindolol (marked ISA). The effects on lymphocyte beta 2-adrenoceptor density--assessed by (+/-)-[125I]iodocyanopindolol (ICYP) binding--were investigated in healthy volunteers aged 23-35 years. None of the test drugs changed the affinity of ICYP for beta 2 adrenoceptors. Propranolol treatment (4 X 40 mg/day) increased the density of beta 2-adrenoceptors by 25% after 2 days; during treatment beta 2-adrenoceptor density remained elevated. After withdrawal of propranolol, beta 2-adrenoceptor density declined slowly, being still significantly increased after 3 days, although propranolol was not detectable in plasma after 24 h, though heart rate was significantly increased. Alprenolol treatment (4 X 100 mg/day) did not significantly affect beta 2-adrenoceptor density. Pindolol treatment (2 X 5 mg/day) caused a 50% decrease of beta 2-adrenoceptor density after 2 days, which remained reduced during treatment. After withdrawal, beta 2-adrenoceptor density was still significantly diminished after 4 days. During and after treatment heart rate was not affected. Bopindolol treatment (2 mg/day) caused a 40% decrease of beta 2-adrenoceptor density after 2 days, which remained reduced during treatment. After withdrawal, beta 2-adrenoceptor density was still significantly diminished after 4 days. During and after treatment heart rate was not affected. It is concluded that the ISA may play an important role in modulating beta 2-adrenoceptor density and hence tissue responsiveness to beta-adrenoceptor stimulation.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1979

[Beta-blockader, pindolol, in the therapy of angina pectoris; a report on a multicentric controlled study].

68 patients with angina pectoris were treated 14 days with placebo and four weeks with 15 mg/die pindolol (Visken) in a double blind multicenter study. The patients were divided into two groups at random: group I received pindolol/placebo, group II pacebo/pindolol. Pindolol reduced in both groups significantly the number and intensity of angina pectoris attacks and the consumption of nitroglycerin capsules. There was no evidence for a rebound phenomenon after abrupt cessation of pindolol treatment. In the wash out period still a relevant antianginous effect of the beta-blocker could be observed. The oxygen demand of the myocardium was reduced by reduction of systolic blood pressure and heart rate whereas diastolic blood pressure remained unchanged. The tolerance of the preparation was good.

Angina Pectoris↗
PubMed1975

The fate of a bacterial plasmid in mammalian cells.

When hamster cells are infected with the bacterial plasmid colicinogenic factor E1 (ColE1), as much as 5-8% of the input plasmid radioactivity is found in the recipient cell, mainly in the nuclear fraction. Density shift experiments with bromodeoxyuridine labeled ColE1 DNA indicate that part of the input DNA may be replicated in the nucleus. ColE1 specific RNA but no colicin E1, can be detected during the first two generations after the uptake of ColE1 DNA. However, extrachromosomal ColE1 DNA is unstable in the mammalian cells and is degraded to acid soluble fragments after a few generations.

Animals↗